Drugs that contain Canagliflozin; Metformin Hydrochloride

1. List of Invokamet drug patents

INVOKAMET's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(1 year, 4 months from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(2 years from now)

Market Authorisation Date: 08 August, 2014

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's patent expiration?
More Information on Dosage

INVOKAMET family patents

45

United States

14

Japan

11

European Union

10

China

9

Argentina

9

Taiwan, Province of China

8

EA

8

South Africa

8

Canada

8

Australia

7

Ukraine

6

Spain

5

New Zealand

5

Norway

5

Korea, Republic of

5

Ecuador

4

Malaysia

4

Brazil

4

Costa Rica

4

Mexico

4

Yugoslavia

4

Iceland

4

Israel

3

Portugal

3

Croatia

3

Peru

3

Cyprus

3

Slovenia

3

Poland

3

Denmark

2

Singapore

2

Hungary

2

ME

2

RS

1

El Salvador

1

Uruguay

1

Panama

1

Guatemala

1

Colombia

1

Hong Kong

1

Honduras

1

Nicaragua

1

Lithuania

1

Luxembourg

1

Chile

1

Netherlands

2. List of Invokamet Xr drug patents

INVOKAMET XR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(1 year, 4 months from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(2 years from now)

Market Authorisation Date: 20 September, 2016

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of INVOKAMET XR before it's patent expiration?
More Information on Dosage

INVOKAMET XR family patents

45

United States

14

Japan

11

European Union

10

China

9

Argentina

9

Taiwan, Province of China

8

EA

8

South Africa

8

Canada

8

Australia

7

Ukraine

6

Spain

5

New Zealand

5

Norway

5

Korea, Republic of

5

Ecuador

4

Malaysia

4

Brazil

4

Costa Rica

4

Mexico

4

Yugoslavia

4

Iceland

4

Israel

3

Portugal

3

Croatia

3

Peru

3

Cyprus

3

Slovenia

3

Poland

3

Denmark

2

Singapore

2

Hungary

2

ME

2

RS

1

El Salvador

1

Uruguay

1

Panama

1

Guatemala

1

Colombia

1

Hong Kong

1

Honduras

1

Nicaragua

1

Lithuania

1

Luxembourg

1

Chile

1

Netherlands

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in